Mucopolysaccharidosis I - 56 Studies Found

Active, not recruiting : Psychological Concomitants of Morquio A Syndrome - Longitudinal Effects of Enzyme Replacement Therapy (The MAPLE Study)
:
  • Morquio A Syndrome
  • Mucopolysaccharidosis IV A

: 2014-08-01
Withdrawn : Dynamic Gait Analysis in Children With Mucopolysaccharidosis Type IVa
:
  • Mucopolysaccharidosis IV
  • Morquio A Disease

: 2014-05-28
Completed : Screening an Orthopedic Population for Mildly-affected Individuals With Morquio Syndrome A and Maroteaux-Lamy Syndrome
:
  • Morquio Syndrome A
  • Maroteaux Lamy Syndrome
  • MPS IVA
  • Morquio Syndrome

: 2013-08-08
Recruiting : A Multicenter, Multinational, Observational Morquio A Registry Study (MARS)
:
  • Mucopolysaccharidosis IV Type A
  • Morquio A Syndrome
  • : 2014-10-28
    : Drug: Vimizim® (elosulfase alfa) Recombinant human N acetylgalactosamine 6 sulfatase (rhGALNS)
Completed : Long-Term Efficacy and Safety Extension Study of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)
:
  • Mucopolysaccharidosis IV A
  • Morquio A Syndrome
  • Drug: BMN 110 - Weekly

Terminated : A Clinical Assessment Study of Subjects With Mucopolysaccharidosis IVA (Morquio Syndrome)
:
  • MPS IV A
  • Mucopolysaccharidosis IVA
  • Morquio A Syndrome

    • : 2008-11-06
Completed : A Double-Blind Study to Evaluate the Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)
: MPS IV A
: 2011-01-10
:
  • Drug: BMN 110 Weekly BMN 110 W
Approved for marketing : BMN 110 US Expanded Access Program
:
  • Mucopolysaccharidosis IVA
  • Morquio A Syndrome
  • MPS IVA

    • : 2013-05-15
    : Drug: BMN 110
Terminated : A Study to Evaluate the Long-Term Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)
:
  • MPS IV A
  • Mucopolysaccharidosis IVA
  • Morquio A Syndrome

    • : 2010-10-28
    : Drug: BMN 110 Patients will receive an intravenous infusion of BMN110 at 2.0mg/kg/week, over a period of
<<< Previous | Next >>>